NM_000136.3:c.843+1G>T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000136.3(FANCC):c.843+1G>T variant causes a splice donor, intron change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000136.3 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FANCC | NM_000136.3 | c.843+1G>T | splice_donor_variant, intron_variant | Intron 8 of 14 | ENST00000289081.8 | NP_000127.2 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Fanconi anemia Pathogenic:1
Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in FANCC are known to be pathogenic (PMID: 17924555). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. Disruption of this splice site has been observed in individual(s) with breast cancer (PMID: 30630526). This variant is not present in population databases (ExAC no frequency). This sequence change affects a donor splice site in intron 8 of the FANCC gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.843+1G>T intronic variant results from a G to T substitution one nucleotide after coding exon 7 of the FANCC gene. RNA studies have demonstrated that a different alteration impacting the same splice donor site, c.843+5G>A, results in abnormal splicing in the set of samples tested (Ambry internal data). A different alteration at this nucleotide, c.843+1G>A, alteration was identified as a germline finding in 1/66 Chinese triple negative breast cancer patients who underwent tumor and germline next generation sequencing using a 43-gene panel (Yi D et al. Hum. Genomics, 2019 01;13:4). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.